AstraZeneca jumped about 7% on Friday, its best session in a year, after the Cambridge-headquartered drugmaker outlined a restructuring programme it said would save $1.5 billion annually and fund new pipeline bets. The move lifted the broader FTSE pharma basket and helped the blue-chip index finish October in positive territory for the first time in three months.

London’s headline gauge closed roughly 0.1% higher on the day and more than 1% up for October, even as banks and miners dragged. NatWest Group fell nearly 9% after guiding net interest income below City expectations, a reminder that Healey’s lighter-than-feared bank surcharge did not remove earnings pressure from the sector.

Pharma versus lenders

Pharmaceuticals added 5.1% on the month, the strongest monthly sector performance since February. Investors treated AstraZeneca’s cost programme as evidence that management can self-fund oncology and biologics spending without leaning on debt at a moment when gilt yields remain elevated. BP, reporting a record quarterly net profit, added a small positive read-through for UK-listed multinationals with dollar earnings.

Banks told a different story. Shore Capital estimated Healey’s 15-month rise in the bank corporation tax surcharge from 3% to 6% would trim 2027 attributable earnings by about 4% at Lloyds and NatWest and roughly 1% at Barclays and HSBC—modest versus worst-case rumours, but still a headwind. NatWest’s outlook miss on Friday amplified that narrative.

What holders are watching

Asset allocators said the FTSE’s October win was narrow: a handful of pharma and energy names offset weakness in precious-metal miners tracking gold’s pullback. Mid-cap domestic earners in the FTSE 250 slipped nearly 1% on Friday, underscoring how global revenue lines still dominate the top index.

With the Budget debate resuming in the Commons on Monday and rate expectations firming after September inflation, traders expect volatility around gilt-sensitive banks to persist. AstraZeneca’s rally, by contrast, is being treated as a company-specific efficiency story that can travel even if Westminster noise continues.

Index composition effects

Passive funds tracking the FTSE 100 rebalance quarterly; AstraZeneca’s weight gain pulls automatic flows into the stock regardless of short-term macro headlines. That mechanical bid can exaggerate single-day moves when pharma diverges from banks, as happened into the October month-end close.

Wealth managers running 60/40 models for UK pension schemes said they trimmed gilt duration last week but kept equity beta neutral, citing Budget clarity on defence spending reprioritisation. Aerospace names mentioned in Healey’s speech outperformed domestically focused retailers in the same session.

October context

Consumer staples including British American Tobacco and Unilever posted modest gains on Friday, offering defensive ballast while miners fell with metal prices. The mix produced a narrow monthly win that headline indices mask: breadth was weak even as the level printed green.

Traders entering November will watch Tuesday’s Budget resolution votes for any last-minute amendments affecting bank surcharges or pharma patent boxes. Neither party tabled surprise manuscript changes over the weekend, according to Commons business papers.